Laura Sue Grosmaire

Title: Laura Sue Grosmaire: Innovator in Immunotherapeutics

Introduction

Laura Sue Grosmaire is a prominent inventor based in Hobart, WA (US). She has made significant contributions to the field of immunotherapy, particularly in the development of methods for B-cell reduction. With a total of 3 patents to her name, Grosmaire's work is paving the way for advancements in treating diseases associated with aberrant B-cell activity.

Latest Patents

Grosmaire's latest patents include innovative methods for B-cell reduction using CD37-specific binding molecules. The first patent outlines methods for B-cell reduction in individuals using these specific binding molecules, either alone or in combination with CD20-specific binding molecules. This synergistic approach aims to enhance the effectiveness of treatment for diseases involving abnormal B-cell activity. Additionally, her patents provide humanized CD37-specific binding molecules, further expanding the potential applications of her research.

Career Highlights

Throughout her career, Grosmaire has worked with notable companies such as Aptevo Research and Development LLC and Emergent Product Development Seattle, LLC. Her experience in these organizations has allowed her to collaborate with leading experts in the field and contribute to groundbreaking research in immunotherapeutics.

Collaborations

Grosmaire has collaborated with esteemed colleagues, including Peter Armstrong Thompson and Jeffrey A Ledbetter. These partnerships have facilitated the exchange of ideas and expertise, enhancing the impact of her work in the scientific community.

Conclusion

Laura Sue Grosmaire is a trailblazer in the field of immunotherapeutics, with her innovative patents and collaborations driving advancements in B-cell reduction methods. Her contributions are vital to the ongoing research and development of treatments for diseases related to B-cell activity.